GILDGilead Sciences
Price
+36%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, price roughly fair, growth steady, the market undecided.
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Gilead Sciences (GILD) reported revenue of $7.80B in Q2 2026 (quarter ended Jun 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 80% and net loss of $10.5B. For the full year FY2025, revenue was $29.4B (+2.4% year on year) and net income $8.51B. Its largest product in Q2 2026 was HIV Product Sales at $4.66B, 55% of the disclosed total, well ahead of HIV Products Descovy at 11%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion.Earnings release · press release
- May 20, 2026Supplemental Indenture On May 20, 2026, Gilead Sciences, Inc. (the “Company”) and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee” and, together with the Company, the “Parties”), entered into an Eleventh Supplemental Indenture (the …Material agreement entered · Form 8-K
- May 7, 2026Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $8.54BThe company’s own SEC segment disclosure.
- HIV Product Sales$4.66B55%
- HIV Products Descovy$921.0M11%
- Oncology Product$468.0M5%
- Liver Disease$433.0M5%
- Trodelvy$307.0M4%
- HIV Products Genvoya$236.0M3%
- Other (16)$1.52B18%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
The closest names by size in the same industry